Patient characteristics
| Characteristic . | n (%) . |
|---|---|
| Total number of patients | 199 |
| Age, median (range; IQR) | 60 (18-86; 53-67) |
| Sex | |
| Male | 149 (75) |
| Female | 50 (25) |
| Pre-LDC weight, kg median (range; IQR) | 82 (44-130; 69-95) |
| Pre-LDC creatinine, mg/dL median (range; IQR) | 0.9 (0.3-1.9; 0.7-1.1) |
| Pre-LDC estimated GFR, ml/min Median (range; IQR) | 100 (80-128; 32-241) |
| Disease type | |
| DLBCL | 131 (66) |
| tFL | 39 (20) |
| HGBL | 19 (9) |
| Other | 10 (5) |
| Disease stage | |
| I | 14 (7) |
| II | 31 (16) |
| III | 27 (14) |
| IV | 126 (64) |
| Unknown | 1 |
| IPI | |
| 0-1 | 23 (19) |
| 2 | 37 (30) |
| 3 | 48 (39) |
| 4-5 | 16 (13) |
| Unknown | 75 |
| Prior lines of therapy | |
| 1-3 | 121 (61) |
| 4-5 | 55 (28) |
| >5 | 23 (12) |
| Bulky disease (≥10 cm) | |
| Yes | 30 (15) |
| No | 168 (85) |
| Unknown | 1 |
| Bridging therapy | |
| Yes | 127 (64) |
| No | 72 (36) |
| Pre-LDC LDH, U/L, median (range) | 252 (115-4655) |
| Estimated fludarabine exposure, mgh/L, median (range) | 16.5 (9.3-23.3) |
| Characteristic . | n (%) . |
|---|---|
| Total number of patients | 199 |
| Age, median (range; IQR) | 60 (18-86; 53-67) |
| Sex | |
| Male | 149 (75) |
| Female | 50 (25) |
| Pre-LDC weight, kg median (range; IQR) | 82 (44-130; 69-95) |
| Pre-LDC creatinine, mg/dL median (range; IQR) | 0.9 (0.3-1.9; 0.7-1.1) |
| Pre-LDC estimated GFR, ml/min Median (range; IQR) | 100 (80-128; 32-241) |
| Disease type | |
| DLBCL | 131 (66) |
| tFL | 39 (20) |
| HGBL | 19 (9) |
| Other | 10 (5) |
| Disease stage | |
| I | 14 (7) |
| II | 31 (16) |
| III | 27 (14) |
| IV | 126 (64) |
| Unknown | 1 |
| IPI | |
| 0-1 | 23 (19) |
| 2 | 37 (30) |
| 3 | 48 (39) |
| 4-5 | 16 (13) |
| Unknown | 75 |
| Prior lines of therapy | |
| 1-3 | 121 (61) |
| 4-5 | 55 (28) |
| >5 | 23 (12) |
| Bulky disease (≥10 cm) | |
| Yes | 30 (15) |
| No | 168 (85) |
| Unknown | 1 |
| Bridging therapy | |
| Yes | 127 (64) |
| No | 72 (36) |
| Pre-LDC LDH, U/L, median (range) | 252 (115-4655) |
| Estimated fludarabine exposure, mgh/L, median (range) | 16.5 (9.3-23.3) |
DLBCL, diffuse large B-cell lymphoma; GFR, glomerular filtration rate (by Cockcroft-Gault equation); HGBL, high-grade B-cell lymphoma; IPI, International Prognostic Index; IQR, interquartile range; LDC, lymphodepleting chemotherapy; tFL, transformed follicular lymphoma.